Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 9/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SCN1A | P35498 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.35 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25331313 | 0.85 | SCN5A (0.38) | SCN4ASCN5ALMNASCN1ASCN9A | |
| SCHEMBL25329836 | 0.77 | SCN5A (0.33) | SCN5A | |
| SCHEMBL25331693 | 0.75 | SCN5A (0.35) | SCN5ALMNACYP1A2MEN1KMT2A | |
| SCHEMBL29707444 | 0.74 | SCN4A (0.52) | SCN4ASCN5ALMNASCN1ASCN9A | |
| SCHEMBL28820152 | 0.73 | KMT2A (0.42) | LMNAALDH1A1GAAMEN1KMT2A | |
| SCHEMBL25328924 | 0.73 | SCN5A (0.47) | SCN4ASCN5ALMNASCN1ASCN9A | |
| SCHEMBL30356486 | 0.71 | SCN5A (0.33) | SCN5A | |
| SCHEMBL25329331 | 0.71 | SCN5A (0.33) | SCN5A | |
| SCHEMBL8238232 | 0.70 | SCN4A (0.70) | SCN4ASCN5ALMNASCN1ASCN9A | |
| SCHEMBL13676826 | 0.70 | ALDH1A1 (0.32) | SCN4ASCN5ALMNASCN1ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256521-A1 | TOPICAL FORMULATIONS AND USES THEREOF | OCULAR TECHNOLOGIES SARL (CH) | 2016-09-08 | — | — | US | disclosed |
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| US-20150165048-A1 | TOPICAL FORMULATIONS AND USES THEREOF | SUN PHARMA GLOBAL FZE (AE) | 2015-06-18 | — | — | US | disclosed |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8673881-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20120122816-A1 | COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION | RESOLVYX PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20110190242-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20100035989-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS | RESOLVYX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20090137527-A1 | Compositions and methods for modulating immune function | RESOLVYX PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090118243-A1 | Compositions and methods for the treatment of ophthalmic conditions | RESOLVYX PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | ALOX15B, ALOX5, ALOX15 | SCN4A 4629/4885SCN5A 2874/4885LMNA 303/4885 |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | SCN4A 4531/4885SCN5A 4594/4885LMNA 1331/4885 |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | ALOX15B, ALOX12, ALOX15 | SCN4A 4032/4885SCN5A 2601/4885LMNA 812/4885 |
| US-20150165048-A1 | TOPICAL FORMULATIONS AND USES THEREOF | LIPA, MGLL, LIPC | SCN4A 4247/4885SCN5A 3378/4885LMNA 987/4885 |
| US-20090118243-A1 | Compositions and methods for the treatment of ophthalmic conditions | ALOX15B, ALOX5, ALOX12 | SCN4A 4116/4885SCN5A 1939/4885LMNA 571/4885 |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | ALOX15B, ALOX5, ALOX12 | SCN4A 4793/4885SCN5A 4000/4885LMNA 891/4885 |
| US-20110190242-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | ALOX15B, ALOX12, ALOX15 | SCN4A 4187/4885SCN5A 3128/4885LMNA 623/4885 |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | SCN4A 4531/4885SCN5A 4594/4885LMNA 1331/4885 |
| US-20160256521-A1 | TOPICAL FORMULATIONS AND USES THEREOF | LIPA, MGLL, LIPC | SCN4A 4247/4885SCN5A 3378/4885LMNA 987/4885 |
| US-20120122816-A1 | COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION | ALOX5, ALOX15B, ALOX12 | SCN4A 4686/4885SCN5A 3967/4885LMNA 327/4885 |
| US-20100035989-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS | ALOX15B, ALOX5, ALOX12 | SCN4A 4644/4885SCN5A 2610/4885LMNA 1692/4885 |
| US-20090137527-A1 | Compositions and methods for modulating immune function | ALOX15B, ALOX12, ALOX5 | SCN4A 4255/4885SCN5A 3154/4885LMNA 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.